Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults
- Conditions
- Human Influenza
- Interventions
- Biological: Inactivated Influenza VaccineBiological: Recombinant Influenza Vaccine
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 254648
- Registration Number
- NCT02600585
- Locations
- 🇺🇸
Kaiser Permanente Vaccine Study Center, Oakland, California, United States
Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
- Conditions
- Influenza
- Interventions
- Biological: PanblokBiological: rHA adjuvant
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 407
- Registration Number
- NCT02464163
- Locations
- 🇺🇸
Meridian Clinical Research, Omaha, Nebraska, United States
🇺🇸Regional Clinical Research, Inc., Endwell, New York, United States
🇺🇸Avail Clinical Research, DeLand, Florida, United States
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
- Conditions
- Influenza
- Interventions
- Biological: Flublok QuadrivalentBiological: Inactivated Influenza Vaccine (IIV4)
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 1350
- Registration Number
- NCT02290509
- Locations
- 🇺🇸
Clinical Research of South Florida, Coral Gables, Florida, United States
🇺🇸Benchmark Research - Sacramento, Sacramento, California, United States
🇺🇸Meridian Clinical Research, Omaha, Nebraska, United States
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
- Conditions
- Influenza
- Interventions
- Biological: Inactivated Influenza VaccineBiological: Flublok Quadrivalent Influenza Vaccine
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 9003
- Registration Number
- NCT02285998
- Locations
- 🇺🇸
Wake Research, Raleigh, North Carolina, United States
🇺🇸Jean Brown Research, Salt Lake City, Utah, United States
🇺🇸Lynn Institute of the Rockies, Colorado Springs, Colorado, United States
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
- Conditions
- Influenza
- Interventions
- Biological: Fluarix Quadrivalent® Influenza Virus VaccineBiological: Flublok® Quadrivalent Influenza Virus Vaccine
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 219
- Registration Number
- NCT01959945
- Locations
- 🇺🇸
Maine Research Associates, LLC, Auburn, Maine, United States
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
- Conditions
- Influenza
- Interventions
- Biological: AfluriaBiological: Flublok
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 2640
- Registration Number
- NCT01825200
- Locations
- 🇺🇸
Genova Clinical Research, Tucson, Arizona, United States
🇺🇸Clinical Research of South Florida, Coral Gables, Florida, United States
🇺🇸Heartland Research Associates, LLC, Wichita, Kansas, United States
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
- Conditions
- Influenza
- Interventions
- Biological: PanBlokBiological: rHA adjuvant
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 341
- Registration Number
- NCT01612000
- Locations
- 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Rochester Center for Vaccine Studies, Rochester, New York, United States
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
- Conditions
- Influenza
- Interventions
- Biological: 0.5mL Intramuscular Injection
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2012-11-26
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 392
- Registration Number
- NCT01147068
- Locations
- 🇺🇸
Vince and Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Meridian Clinical Research, Omaha, Nebraska, United States
Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
- Conditions
- Influenza
- Interventions
- Biological: FluBlok Influenza VaccinationBiological: TIV (Fluzone) Influenza Vaccination
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2011-07-27
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 602
- Registration Number
- NCT00539864
- Locations
- 🇺🇸
Kaiser Permanente Pediatric Clinic - Fresno, Fresno, California, United States
🇺🇸Kaiser Permanente Pediatric Clinic - Hayward, Hayward, California, United States
🇺🇸Kaiser Permanente Pediatric Clinic - Roseville, Roseville, California, United States
Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
- Conditions
- Influenza
- Interventions
- Biological: Influenza Vaccination
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2009-12-17
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 870
- Registration Number
- NCT00395174
- Locations
- 🇺🇸
Passport Health Maryland, Baltimore, Maryland, United States
🇺🇸Passport Health New Jersey, Shrewsbury, New Jersey, United States
🇺🇸Center of Vaccine Development, Univ. of Maryland, Baltimore, Maryland, United States